- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
III
II
Principal Investigator(s)
Kachit Choopanya, MD
Objective
To assess the safety and efficacy of daily tenofovir to prevent parenteral HIV infection among injection drug users (IDU) in Thailand. IDU was defined as individuals who reported substance use in the past year from the time they were screened.
Key results: There was a 49% reduction in HIV infection rate among IDU in Thailand with Daily oral TDF.
Last update August 10, 2022
Prevention Option(s)
PrEP
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Description
Daily dosing
Mode of Delivery
Tablet
Products
TDF
ARMs
Experimental
Description
Daily dosing
Mode of Delivery
Tablet
ARMs
Placebo Comparator
Official Code
Related Publications
Trial Sponsors
Bangkok Metropolitan Administration Medical College and Vajira Hospital, Thailand Ministry of Health, US CDC
Product Developers
Gilead Sciences, Inc.
June 2005
October 2014
Date of Enrollment Completion
July 1, 2013
Enrollment
2 413
20
Years
60
Years
Population
Injecting drug users
Sites
Site(s) - Thailand
Thailand